Trials / Recruiting
RecruitingNCT06387628
LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
A Phase II Single Center Two Cohorts Trial of LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 74 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of LM108 plus toripalimab plusnab-paclitaxel or eribulin as first-line or post-line treatment in patients with metastatic triple-negative breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LM-108 | LM-108, 10mg/kg, d1, q6w |
| DRUG | Toripalimab | Toripalimab, 240 mg, d1, q3w |
| DRUG | Eribulin | Eribulin 1.4 mg/m2, d1, 8 , q3w |
| DRUG | Nab paclitaxel | Nab paclitaxel 125 mg/m2, d1, 8 , q3w |
Timeline
- Start date
- 2024-07-10
- Primary completion
- 2026-04-01
- Completion
- 2027-04-01
- First posted
- 2024-04-29
- Last updated
- 2024-08-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06387628. Inclusion in this directory is not an endorsement.